Central Pain Study for ABX-1431

Summary

This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy. During the course of this study, each participant will take a daily dose of 20 mg of ABX-1431 or a matching placebo for approximately 7 to 9 weeks.

Timeline

Start

2017-08-01

Primary completion

2018-07-23

Completion

2018-07-24

Drugs

Indications